{
 "context": "The following article called 'BRIEF-Xenon Pharma, Teva Pharma Terminate Development & License Agreement' was published on 2018-03-08. The body of the article is as follows:\n    \nMarch 7 (Reuters) - Xenon Pharmaceuticals Inc:\n* XENON PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE\n* XENON PHARMA - CO, TEVA PHARMACEUTICALS INTERNATIONAL GMBH, TEVA CANADA, ENTERED DEAL TO MUTUALLY TERMINATE DEC 7, 2012 DEVELOPMENT & LICENSE AGREEMENT\n* XENON PHARMA - AS PER TERMINATION AGREEMENT, TEVA AGREED TO TRANSFER AND ASSIGN 1 MILLION SHARES OF CO HELD BY TEVA CANADA LTD TO CO FOR CANCELLATION Source text for Eikon: Further company coverage:\n \n\n    The day before the article was published, the stock price of Teva Pharmaceutical Industries was 19.06999969482422 and the day after the article was published, the stock price of Teva Pharmaceutical Industries was ",
 "expected": "19.18000030517578",
 "date": "2018-03-08",
 "ticker": "TEVA",
 "company": "Teva Pharmaceutical Industries",
 "url": "https://www.reuters.com/article/brief-xenon-pharma-teva-pharma-terminate/brief-xenon-pharma-teva-pharma-terminate-development-license-agreement-idUSASB0C99D"
}